UY39600A - EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS - Google Patents

EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS

Info

Publication number
UY39600A
UY39600A UY0001039600A UY39600A UY39600A UY 39600 A UY39600 A UY 39600A UY 0001039600 A UY0001039600 A UY 0001039600A UY 39600 A UY39600 A UY 39600A UY 39600 A UY39600 A UY 39600A
Authority
UY
Uruguay
Prior art keywords
growth factor
factor receptor
epidermal growth
receptor inhibitors
compounds
Prior art date
Application number
UY0001039600A
Other languages
Spanish (es)
Inventor
Dmitry Valentinovich Morozov
Kirill Vadimovich Zavialov
Artsiom Evgenievich Shekhautsou
Ilia Alexeevich Smetanin
Georgii Viktorovich Iakobson
Shamil Dinarovich Kadyrov
Adel Ravilevich Khaidarov
Daria Dmitrievna Beketova
Daniel Evgenevich Polianczyk
Ramilia Rinadovna Starodubtseva
Polina Olegovna Suntsova
Dmitry Alekseevich Khalabudin
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021137120A external-priority patent/RU2021137120A/en
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of UY39600A publication Critical patent/UY39600A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators

Abstract

La presente invención se refiere a nuevos compuestos de la fórmula I o sal, solvato o estereoisómero farmacéuticamente aceptables de los mismos, que tienen propiedades inhibidoras del EGFR, a las composiciones farmacéuticas que contienen dichos compuestos, a los métodos de tratamiento de enfermedades o trastornos y al uso de dichos compuestos como productos farmacéuticos para tratar enfermedades o trastornos.The present invention relates to new compounds of formula I or pharmaceutically acceptable salt, solvate or stereoisomer thereof, having EGFR inhibitory properties, pharmaceutical compositions containing said compounds, methods of treatment of diseases or disorders and to the use of such compounds as pharmaceuticals to treat diseases or disorders.

UY0001039600A 2020-12-30 2021-12-30 EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS UY39600A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2020144141 2020-12-30
RU2021137120A RU2021137120A (en) 2021-12-15 Epidermal growth factor receptor inhibitors

Publications (1)

Publication Number Publication Date
UY39600A true UY39600A (en) 2022-05-31

Family

ID=82259596

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039600A UY39600A (en) 2020-12-30 2021-12-30 EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS

Country Status (3)

Country Link
TW (1) TW202241890A (en)
UY (1) UY39600A (en)
WO (1) WO2022146201A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011079231A1 (en) * 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
WO2011140338A1 (en) * 2010-05-05 2011-11-10 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
CN104140418B (en) * 2014-08-15 2016-08-24 常州润诺生物科技有限公司 2-(2,4,5-substituted aniline) pyrimidine derivatives and application thereof
EP3205650B1 (en) * 2014-10-11 2021-08-04 Shanghai Hansoh Biomedical Co., Ltd. Egfr inhibitor, and preparation and application thereof

Also Published As

Publication number Publication date
WO2022146201A1 (en) 2022-07-07
TW202241890A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
ECSP19044159A (en) AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
CL2018001145A1 (en) Jak kinase inhibitor compounds for the treatment of respiratory disease
CL2020002562A1 (en) (divisional application 1097-2020) pyridinecarbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors.
CO2021002977A2 (en) Dimethylaminoazetidinamines as jak inhibitors
CO2020015758A2 (en) Purinone compounds and their use in the treatment of cancer
EA201792214A1 (en) COMPOUNDS OF SUBSTITUTE QUINAZOLINE
EA201790122A1 (en) DERIVATIVES OF 2-H-INDAZOL AS AN INHIBITOR OF CYCLIN-DEPENDENT KINAZ (CDK) AND THERAPEUTICALLY USED
BR112021007788A8 (en) Jak 2-azabicyclohexane inhibitor compound
CY1124243T1 (en) INHIBITING THE A1 TRANSIENT POTENTIAL RECEPTOR ION CHANNEL
EA201800064A1 (en) 1,1,1-TRIFTOR-3-HYDROXYPROPAN-2-IL CARBAMATE DERIVATIVES AND 1,1,1-TRIFTOR-4-HYDROXYBUTAN-2-IL CARBAMATE DERIVATIVES AS MIGL INHIBITORS
CU20190080A7 (en) ISOINDOLINE DERIVATIVES USEFUL TO TREAT NON-ALCOHOLIC STEATOHEPATITIS AND OTHER DYSFUNCTIONAL HEALING DISEASES OF THE TISSUE AND FIBROSIS
CO2021002976A2 (en) 5- to 7-membered heterocyclic amides as jak inhibitors
CO2019009423A2 (en) Piperidine Substituted MNK Inhibitors and Related Methods
CO2021005532A2 (en) Quinoline derivatives as inhibitors of integrin alpha4beta7
ECSP14007965A (en) FORMULATIONS OF (+) - 2- [1- (3-ETOXY-4-METOXY-PHENYL) -2-METANSULPHONYL-ETHYL] -4-ACETYL AMINOISOINDOLIN-1, 3-DIONA
DOP2021000198A (en) COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
DOP2013000314A (en) TYPICAL OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB
CL2022002975A1 (en) Compounds and compositions for inhibiting hif2-alpha activity and their methods of use
EA201790253A1 (en) ALDOSTERONSYNTASE INHIBITORS
EA201790830A1 (en) ALDOSTERONSYNTASE INHIBITORS
MX2020004025A (en) Epidermal growth factor receptor inhibitors.
CY1120608T1 (en) PHARMACEUTICAL ACTIVE COMPOUNDS
BR112017021583A2 (en) Methods for treating inflammatory disorders
BR112018073419A2 (en) combination, use of combination, method for treatment, compound, method for treatment of alzheimer's disease and pharmaceutical composition
UY39600A (en) EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS